At a glance
ClinicalIndex Comparison RecordN/ACompleted· 119 enrolled
Drug / intervention
Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surfacedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Study of the GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease (VIPER)
In Brief
A clinical study evaluating Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface for Peripheral Vascular Diseases. Completed, enrolled 119 participants across 5 sites.
Detailed Summary
The objective of the study is collect data on the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in the treatment of chronic Superficial Femoral Artery disease. Device patency at 12 months is the primary endpoint.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Vascular Diseases
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedOct 2007
Primary CompletionJun 2011
TodayJul 2026
First PostedOct 10, 2007
Enrollment StartOct 1, 2007
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.7 years ago
Interventions
Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surfacedevice
Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface